15results about How to "Reduce lipid accumulation" patented technology

The invention relates to the technical field of drugs for gene therapy, in particular to application of CAP-Gly functional peptide in preparation of drugs for treating fatty liver. The invention provides application of a CAP-Gly functional peptide or a reagent for improving the expression quantity of the CAP-Gly functional peptide in preparation of a medicine for treating fatty liver. The amino acid sequence of the CAP-Gly functional peptide is shown as SEQ ID NO.23. The invention further provides a preparation method of the CAP-Gly functional peptide. The invention finds that the overexpression of the KIF13B protein or the CAP-Gly functional peptide thereof in mice can effectively reduce lipid accumulation in liver cells and increase phosphorylation of protein kinase alpha activated by adenosine monophosphate, and provides a new target and a new strategy for precise treatment of patients with fatty liver (especially metabolism-related fatty liver diseases) clinically.

This invention relates to a lipid-lowering synbiotic, its preparation method, and its application, belonging to the field of egg-laying hen farming technology. The lipid-lowering synbiotic of this invention comprises the following components in parts by weight: 3-85 parts of traditional Chinese medicine extract, 1-25 parts of probiotics, 3-30 parts of prebiotics, 1-16 parts of enzyme preparation, and 4-55 parts of dietary therapy components. This synbiotic not only significantly improves the lipid metabolism of laying hens but also significantly prolongs the peak egg-laying period, increases the egg production rate, reduces cholesterol content in egg yolks, promotes calcium and phosphorus absorption, and reduces the paralysis rate in laying hens. It comprehensively improves the economic benefits of egg-laying hen farming.

The invention discloses application of a miR-497a-5p inhibitor in preparation of a medicine for preventing or treating liver diseases, and the miR-497a-5p gene can be used as a regulation target or a regulation marker in the medicine for preventing or treating the liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The invention proves that the miR-497a-5p inhibitor can be used for preventing or treating the liver diseases on an animal model of the liver related diseases.

The invention provides an application of isodan leaf emodin in preparation of a medicine for preventing and treating acetaminophen-induced acute liver injury. The invention proves that the isodan-leaf emodin can obviously relieve the acute liver injury symptom induced by acetaminophen, the relieving effect is closely related to the fatty acid oxidation promoting capability of the isodan-leaf emodin, and the new application of the isodan-leaf emodin in pharmacology, new drug research and development and clinical treatment is expanded.

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of timosaponin BII in preparation of a medicine for preventing and treating alcoholic liver injury. A novel KEAP1-NRF2 inhibitor-TBII is found through a virtual screening method, TBII and KEAP1 protein have high affinity, and experiments verify that TBII can reduce the protein level of KEAP1 in vivo and improve protein expression of NRF2 and downstream targets NQO1 and GCLC of NRF2. It is proved that TBII can protect the liver function by inhibiting increase of AST and ALT content, oxidative stress and lipid accumulation of the liver are reduced, and TBII has the potential to become a medicine for treating ethanol-induced liver injury.

The present invention relates to the use of fermented lactobacillus grx08 in the preparation of food, functional food and medicine with the effect of alleviating alcoholic liver damage and related symptoms thereof, and the preservation number of the fermented lactobacillus grx08 is CGMCC No: 7695. The fermented lactobacillus grx08 has the effect of reducing alcohol dehydrogenase and alleviating and restoring the balance of ethanol metabolism. The fermented lactobacillus grx08 has the effect of reducing alanine aminotransferase, reducing liver lipid accumulation, reducing liver lipid peroxidation products, and alleviating liver damage. Animal experiments have shown that fermented lactobacillus grx08 (CGMCC No: 7695) can restore the metabolic balance of rat alcohol dehydrogenase, reduce the level of alanine aminotransferase, reduce lipid accumulation and lipid peroxides in the liver, and alleviate liver damage. In addition, fermented lactobacillus grx08 can also alleviate kidney damage, enhance the tight connectivity of rat intestines, reduce inflammatory factors in the body, and alleviate the increase in blood sugar caused by acute alcohol intervention.

The invention belongs to the technical field of medicines, and particularly relates to application of a clinopodium chinense extract in preparation of a medicine for preventing or treating a non-alcoholic fatty liver disease. Wherein the calamint is subjected to crushing, alcohol extraction and reduced pressure recovery to obtain a concentrate, the concentrate is extracted by petroleum ether and ethyl acetate to obtain an ethyl acetate extract, and the ethyl acetate extract is purified by macroporous resin to obtain the calamint extract. The extract obviously inhibits the accumulation of HepG2 cell lipid induced by palmitic acid, increases PPARalpha and CPT1A, reduces the protein expression of SREBP-1c, FASN and CD36, and inhibits the oxidative stress of liver cells. The extract can also obviously relieve lipid accumulation of NAFLD mice induced by high fat diet, improve oxidation resistance and relieve liver injury. The extract inhibits the activity of alpha-glucosidase and increases the expression of an adiponectin receptor 2. It is shown that the clinopodium megalanthum extract can effectively reduce blood fat, relieve liver lipid accumulation and inhibit oxidative stress, has the effects of inhibiting sugar absorption and protecting liver cells, and can be used for relieving the development of NAFLD.

The invention belongs to the technical field of food processing, and particularly relates to common turnip and highland barley composite high-calcium biscuits and a preparation method thereof. Brassica rapa and highland barley powder and ultrapure water are mixed, heated and stirred, brassica rapa and highland barley gel with a three-dimensional network structure is formed, the mixed homogenate is fully adsorbed, and the prepared satiety gel particles effectively reduce absorption of the body to sugar and fat; flavor zymophyte liquid obtained through constant-temperature culture is used for fermenting the mixed flour to increase the volume and elasticity of dough, the emulsion for promoting calcium absorption is mixed with calcium carbonate and calcium hydrophosphate, freezing nano spray drying is performed, and obtained high-calcium particles easy to absorb promote calcium ions in blood to deposit into bones; the surfaces of the baked biscuits are evenly coated with a caries-preventing stability-maintaining solution, the made common turnip and highland barley composite high-calcium biscuits are good in flavor and crisp in taste, abdominal distension and obesity cannot be caused by long-term eating, blood sugar rise cannot be caused, and calcium components contained in the common turnip and highland barley composite high-calcium biscuits can be easily absorbed by organisms.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The invention provides application of PCSK9 in preparation of a medicine for treating metabolic steatohepatitis or related diseases thereof, and relates to the technical field of biology. According to the invention, the MASH model is constructed by utilizing methionine choline lacking feed, and the PCSK9 protein expression level in liver and serum is obviously increased; liver lipid accumulation of a PCSK9 gene knockout mouse is remarkably reduced, both liver inflammation and liver fibrosis are relieved, and the liver function is remarkably improved; and the silenced liver PCSK9 can be used for treating MASH, so that a theoretical basis is provided for preparing medicines for preventing and / or treating metabolic steatohepatitis or related diseases thereof, and a new medicine treatment target is provided.

The invention discloses an application of a mulberry flavonol extract in preparation of a hypoglycemic drug, and belongs to the technical field of biology. According to the application of the mulberry flavonol extract in the preparation of the hypoglycemic drug, an insulin resistance model is established by utilizing HepG2 cells, and the mulberry flavonol extract acts on IR-HepG2 cells; the influence of the mulberry flavonol extract on cell glucose consumption, glycogen synthesis, glycometabolism, lipid metabolism, oxidative stress and glycolysis key enzyme gene expression quantity is analyzed, and the insulin resistance improving effect of the mulberry flavonol extract is verified from the cell level.

The present invention relates to the field of microbial technology, and in particular to a strain of animal-associated Lactobacillus LA-1, a microbial preparation and an application thereof. Animal Lactobacillus ) LA‑1 has been deposited in the General Microbiology Center of China National Committee for the Preservation of Microbiological Cultures on September 27, 2024, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 32098. Animal-associated Lactobacillus LA‑1 has the effect of significantly reducing cholesterol content and bile salt hydrolase activity, and can inhibit α-glucosidase activity, has a high fatty acid absorption rate, is safe and sensitive to commonly used antibiotics, can relieve obesity, reduce blood lipids and liver lipid accumulation, relieve liver lipid degeneration and fat hypertrophy, has the effect of protecting the liver and enhancing liver function, and has good application prospects in the preparation of functional products.

The invention belongs to the technical field of medicines, and relates to application of X201415 acting on GPR75 protein in preparation of drugs for treating non-alcoholic steatohepatitis. Experiments show that the lipid-lowering effect of the GPR75 protein in liver cells is achieved through the GPR75 protein. In CDAHFD-induced NASH mice, after X201415 treatment, the liver morphology of the mice is improved, the body weight and the liver index are reduced, and the TC and TG contents of the liver are remarkably reduced; in addition, the epididymis fat volume is also significantly reduced. Liver histomorphology shows that X201415 can effectively improve lipid metabolism disorder and fibrosis degree, so that liver lobules are arranged more orderly, and fat accumulation and collagenous fibers are reduced; the expression level of lipid metabolism related genes is reduced, and synthesis of fatty acid and triglyceride is inhibited. Meanwhile, the X201415 obviously inhibits the expression of inflammatory factor genes and fibrosis related genes, and shows the potential efficacy of the medicine in the process of regulating and controlling inflammation and fibrosis. Experimental basis and thought are provided for X201415 synthesis, a new target spot and application of the new target spot in NASH.

The invention belongs to the technical field of biological medicine, and particularly discloses application of glaucocalyxin A in preparation of medicine for preventing / treating non-alcoholic fatty liver disease. It is proved for the first time that GLA reduces lipid accumulation and resists oxidative stress through an Nrf2-ARE endogenous antioxidant pathway, has an obvious improvement effect on NAFLD, is expected to serve as an alternative medicine for treating NAFLD subsequently, and has potential application value in clinical treatment of the NAFLD.

The invention discloses application of CPTH2 to improvement of liver fatty degeneration caused by an LXR agonist. LXR activation has been demonstrated to have both an ideal result (increasing cholesterol reverse transport) and a bad result (increasing liver adipogenesis) for rodents and primates. The research shows that the combined use of the CPTH2 and the LXR agonist can relieve the increase of triglyceride (TG) in the liver and glutamic oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT) indexes of liver injury in serum. Therefore, the CPTH2 can be applied to preparation of the medicine for improving liver fatty degeneration caused by the LXR agonist. The combination of the CPTH2 and the LXR agonist can be applied to preparation of medicines for treating liver fatty degeneration.